The Journal of Practical Medicine >
Impact of sintilimab combined with TP chemotherapy regimen on immune function and prognostic survival in patients with advanced esophageal cancer
Received date: 2025-06-30
Online published: 2025-09-25
Objective To investigate the impact of sintilimab combined with TP chemotherapy regimen on immune function and prognostic survival in patients with advanced esophageal cancer. Methods A total of 82 patients with advanced esophageal cancer who received treatment in the hospital from January 2022 to October 2023 were enrolled. They were divided into two groups with 41 cases in each group using the random number table method. The control group was given the TP chemotherapy regimen， while the observation group was treated with sintilimab in addition to the TP chemotherapy regimen used in the control group. The treatment cycle was 21 days， and both groups received 4 cycles of treatment. After that， the observation group received sintilimab monotherapy for maintenance treatment for at least 1 year. The disease control rate （DCR） and objective response rate （ORR） of the patients were recorded. The immune function， levels of inflammatory factors and tumor markers before and after treatment were compared between the two groups. The swallowing function and quality of life of the patients before and after treatment were evaluated using the Swallowing Safety Assessment （SSA） and the Quality of Life Instruments for Cancer Patients - Esophageal Cancer （QLICP-ES）. The occurrence of adverse reactions was also recorded. After the start of treatment， the patients were followed up for 18 months， and the overall survival （OS） and survival rate were recorded. Results In the observation group， the partial remission rate and disease control rate were 53.66% and 87.80% respectively， both higher than those in the control group. After treatment， the levels of CD3+ and CD4+ in the observation group were （50.48 ± 5.61）% and （37.96 ± 4.69）% respectively， which were higher than （44.73 ± 5.12）% and （33.15 ± 4.21）% in the control group. The immune function of the observation group was improved compared with the control group， while the levels of inflammatory factors and tumor markers were lower than those in the control group. The swallowing function and quality of life were significantly improved compared with the control group （P < 0.05）.The 18-month follow-up results showed that the median overall survival （OS） in the observation group was 16 （9， 17） months， and that in the control group was 9 （7， 14） months. The OS in the observation group was longer than that in the control group （χ2 = 13.394， P < 0.001）. The 18months survival rates in the observation group and the control group were 60.98% （25/41） and 36.59% （15/41） respectively， with the observation group being higher than the control group （χ2 = 4.881， P = 0.027）. Conclusion The sintilimab combined with TP chemotherapy regimen is beneficial for improving immune function and enhancing the survival status of patients with advanced esophageal cancer.
Jingguo LI , Yan LIU , Chao WANG , Chenghui LI . Impact of sintilimab combined with TP chemotherapy regimen on immune function and prognostic survival in patients with advanced esophageal cancer[J]. The Journal of Practical Medicine, 2025 , 41(18) : 2906 -2912 . DOI: 10.3969/j.issn.1006-5725.2025.18.018
| [1] | 王豪，陆筱祎，王文杰. 老年局部晚期食管癌同步放化疗序贯信迪利单抗免疫治疗的疗效［J］. 实用医学杂志， 2025， 41（3）： 365-370. |
| [2] | ASEFA T， TESFAYE W， BITEW G， et al. Lived experiences of dysphagia-related quality of life among esophageal cancer patients： A qualitative study［J］. Health Qual Life Outcomes， 2025， 23（1）：2. doi:10.1186/s12955-024-02319-x |
| [3] | 游传宇，皈燕. 不可切除局部晚期食管鳞癌维持治疗的研究进展［J］. 中国肿瘤临床，2025，52（5）：253-258. |
| [4] | ZHENG W， FU L. Effect of thalidomide combined with TP chemotherapy on serum VEGF and NRP-1 levels advanced esophageal cancer patients［J］. Am J Transl Res， 2021， 13（9）：10809-10815. |
| [5] | 刘爱芹，闫冰，任鹏，等. 小牛脾提取物对食管鳞癌术后辅助化疗患者的影响［J］. 中国免疫学杂志，2025，41（5）：1122-1128. |
| [6] | 齐文昕，张伟龙，景红梅. 肿瘤免疫疗法中细胞来源对治疗效果的影响［J］. 中华血液学杂志，2024，45（7）：699-704. |
| [7] | WANG C， JIN L， CHENG X，et al. Real-World Efficacy and Safety of Sintilimab-Based Regimens against Advanced Esophageal Cancer： A Single-Center Retrospective Observational Study［J］. Biomed Res Int， 2022， 2022：7331687. doi:10.1155/2022/7331687 |
| [8] | 葛均波，徐永健，王辰.内科学［M］.9版.北京： 人民卫生出版社，2018：350-352. |
| [9] | 陈俊春，孙丽凯. 标准吞咽功能评估量表在高龄病人饮食护理中的应用［J］. 护理研究，2015，29（10）：1220-1222. |
| [10] | 戚艳波，李高峰，孟琼，等. 食管癌生命质量测定量表QLICP-ES的条目筛选［J］. 国际肿瘤学杂志，2010，37（7）：554-556. |
| [11] | JIANG L， ZHU J， CHEN X，et al. Safety and efficacy of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in neoadjuvant chemoradiotherapy for patients with locally advanced esophageal carcinoma： A retrospective study［J］. Radiat Oncol， 2022， 17（1）：218. doi:10.1186/s13014-022-02190-4 |
| [12] | MAEDA O， FURUNE S， KANDA M，et al. Docetaxel， cisplatin， and fluorouracil with pegfilgrastim on day 3 as neoadjuvant chemotherapy for esophageal cancer［J］. Cancer Med， 2024， 13（2）：e6974. doi:10.1002/cam4.6974 |
| [13] | YOOM H J， KIM G C， OH S，et al. WNK3 inhibition elicits antitumor immunity by suppressing PD-L1 expression on tumor cells and activating T-cell function［J］. Exp Mol Med， 2022， 54（11）：1913-1926. doi:10.1038/s12276-022-00876-z |
| [14] | KOTANIDES H， LI Y， MALABUNGA M，et al. Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity［J］. Cancer Immunol Res， 2020， 8（10）：1300-1310. doi:10.1158/2326-6066.cir-20-0304 |
| [15] | WANG Q， XIE B， LIU S，et al. What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy？［J］. Front Immunol， 2021， 12：773168. doi:10.3389/fimmu.2021.773168 |
| [16] | WU Y Y， SHAO H. Research progress of sintilimab in the treatment of cancer （Review）［J］. Oncol Lett， 2025， 29（5）：240. doi:10.3892/ol.2025.14986 |
| [17] | 焦福智，陈雅蕊，姬薇，等. PD-1抑制剂联合化疗一线新辅助治疗局部进展期胃腺癌的近期疗效及安全性评估［J］. 中国药物警戒，2023，20（3）：301-305. |
| [18] | SEBASTIAN J， RATHINASAMY K. Microtubules and Cell Division： Potential Pharmacological Targets in Cancer Therapy［J］. Curr Drug Targets， 2023， 24（11）：889-918. doi:10.2174/1389450124666230731094837 |
| [19] | BOZDAGANYAN M， FEDOROV V， KHOLINA E，et al. Exploring tubulin-paclitaxel binding modes through extensive molecular dynamics simulations［J］. Sci Rep， 2025， 15（1）：8378. doi:10.1038/s41598-025-92805-z |
| [20] | WANG X， ZHOU Y， WANG D，et al. Cisplatin-induced ototoxicity： From signaling network to therapeutic targets［J］. Biomed Pharmacother， 2023， 157：114045. doi:10.1016/j.biopha.2022.114045 |
| [21] | PARK S Y， CHUNG Y S， PARK S Y，et al. Role of AMPK in Regulation of Oxaliplatin-Resistant Human Colorectal Cancer［J］. Biomedicines， 2022， 10（11）：2690. doi:10.3390/biomedicines10112690 |
| [22] | SHEN G Y， ZHANG Y， HUANG R Z， et al. FOXP4-AS1 promotes CD8+ T cell exhaustion and esophageal cancer immune escape through USP10-stabilized PD-L1［J］. Immunol Res， 2024， 72（4）：766-775. doi:10.1007/s12026-024-09482-9 |
| [23] | XIONG J， CHENG S， GAO X， et al. Anti-metabolic agent pegaspargase plus PD-1 antibody sintilimab for first-line treatment in advanced natural killer T cell lymphoma［J］. Signal Transduct Target Ther， 2024， 9（1）：62. doi:10.1038/s41392-024-01782-8 |
| [24] | GRANDITS M， PALHARES L C G F， OSBORN G，et al. Fc-mediated immune stimulating， pro-inflammatory and antitumor effects of anti-HER2 IgE against HER2-expressing and trastuzumab-resistant tumors［J］. J Immunother Cancer， 2025， 13（3）：e010945. doi:10.1136/jitc-2024-010945 |
| [25] | YE Z M， XU Z， WANG H L，et al. Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus chemotherapy as the first-line treatment for advanced esophageal cancer［J］. Cancer Med， 2023， 12（5）：6182-6189. doi:10.1002/cam4.5350 |
| [26] | LV H， HUANG C， LI J， et al. The survival outcomes of neoadjuvant sintilimab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma［J］. Front Immunol， 2023， 13：1100750. doi:10.3389/fimmu.2022.1100750 |
/
| 〈 |
|
〉 |